Search

Your search keyword '"William Lum"' showing total 3 results
Start Over Author "William Lum" Journal world allergy organization journal
3 results on '"William Lum"'

1. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

Author

Marcus Maurer, MD, Markus Magerl, MD, Stephen Betschel, MD, Werner Aberer, MD, Ignacio J. Ansotegui, MD, PhD, Emel Aygören-Pürsün, MD, Aleena Banerji, MD, Noémi-Anna Bara, MD, Isabelle Boccon-Gibod, MD, Konrad Bork, MD, Laurence Bouillet, Pr, MD, PhD, Henrik Balle Boysen, Nicholas Brodszki, MD, PhD, Paula J. Busse, MD, Anette Bygum, MD, DMSci, Teresa Caballero, MD, PhD, Mauro Cancian, MD, PhD, Anthony J. Castaldo, Danny M. Cohn, MD, PhD, Dorottya Csuka, MD, Henriette Farkas, MD, PhD, DSc, Mark Gompels, MBBS, BSc, MD, Richard Gower, MD, Anete S. Grumach, MD, PhD, Guillermo Guidos-Fogelbach, MD, PhD, Michihiro Hide, MD, PhD, Hye-Ryun Kang, MD, PhD, Allen P. Kaplan, MD, Constance H. Katelaris, MBBS, PhD, Sorena Kiani-Alikhan, PhD, Wei-Te Lei, MD, Richard F. Lockey, MD, Hilary Longhurst, PhD, William Lumry, MD, Andrew MacGinnitie, MD, PhD, Alejandro Malbran, MD, PhD, Inmaculada Martinez Saguer, MD, Juan José Matta Campos, MD, Alexander Nast, MD, Dinh Nguyen, MD, PhD, Sandra A. Nieto-Martinez, MD, Ruby Pawankar, MD, PhD, Jonathan Peter, MB ChB, MMed, FCP (SA), PhD, Grzegorz Porebski, MD, Nieves Prior, MD, PhD, Avner Reshef, MD, Marc Riedl, MD, Bruce Ritchie, MD, Farrukh Rafique Sheikh, MBBS, William B. Smith, MBBS, PhD, Peter J. Spaeth, PhD, Marcin Stobiecki, MD, Elias Toubi, MD, Lilian Agnes Varga, PhD, Karsten Weller, MD, Andrea Zanichelli, MD, Yuxiang Zhi, MD, Bruce Zuraw, MD, and Timothy Craig, MD

Subjects
Hereditary angioedema, C1-inhibitor, diagnosis, GRADE therapy, management, disease control, Immunologic diseases. Allergy, RC581-607
Abstract

Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2), by providing guidance on common and important clinical issues, such as: 1) How should HAE be diagnosed? 2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? 3) What are the goals of treatment? 4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast feeding women? 5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.

Published
2022
Full Text
View/download PDF

2. WAO Guideline for the Management of Hereditary Angioedema

Author

Timothy Craig, DO, Emel Aygören Pürsün, MD, Konrad Bork, MD, Tom Bowen, MD, Henrik Boysen, Henriette Farkas, MD PhD, Anete Grumach, MD PhD, Constance H. Katelaris, MB BS PhD, Richard Lockey, MD, Hilary Longhurst, MD, William Lumry, MD, Markus Magerl, MD, Immaculada Martinez-Saguer, MD PhD, Bruce Ritchie, MD, Alexander Nast, MD, Ruby Pawankar, MD PhD, Bruce Zuraw, MD, and Marcus Maurer, MD

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis and appropriate therapy are often unknown or not available for physicians and other health care providers. For this reason we convened a group of specialists that focus upon HAE from around the world to develop not only a consensus on diagnosis and management of HAE, but to also provide evidence based grades, strength of evidence and classification for the consensus. Since both consensus and evidence grading were adhered to the document meets criteria as a guideline. The outcome of the guideline is to improve diagnosis and management of patients with HAE throughout the world and to help initiate uniform care and availability of therapies to all with the diagnosis no matter where the residence of the individual with HAE exists. Keywords: Hereditary Angioedema, Guidelines, HAE, therapy, management, diagnosis, medications, international

Published
2012
Full Text
View/download PDF

3. Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies

Author

Richard G Gower, MD, Paula J Busse, MD, Emel Aygören-Pürsün, MD, Amin J Barakat, MD, Teresa Caballero, MD, Mark Davis-Lorton, MD, Henriette Farkas, MD, David S Hurewitz, MD, Joshua S Jacobs, MD, Douglas T Johnston, MD, William Lumry, MD, and Marcus Maurer, MD

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Hereditary angioedema (HAE) caused by C1-esterase inhibitor deficiency is an autosomal-dominant disease resulting from a mutation in the C1-inhibitor gene. HAE is characterized by recurrent attacks of intense, massive, localized subcutaneous edema involving the extremities, genitalia, face, or trunk, or submucosal edema of upper airway or bowels. These symptoms may be disabling, have a dramatic impact on quality of life, and can be life-threatening when affecting the upper airways. Because the manifestations and severity of HAE are highly variable and unpredictable, patients need individualized care to reduce the burden of HAE on daily life. Although effective therapy for the treatment of HAE attacks has been available in many countries for more than 30 years, until recently, there were no agents approved in the United States to treat HAE acutely. Therefore, prophylactic therapy is an integral part of HAE treatment in the United States and for selected patients worldwide. Routine long-term prophylaxis with either attenuated androgens or C1-esterase inhibitor has been shown to reduce the frequency and severity of HAE attacks. Therapy with attenuated androgens, a mainstay of treatment in the past, has been marked by concern about potential adverse effects. C1-esterase inhibitor works directly on the complement and contact plasma cascades to reduce bradykinin release, which is the primary pathologic mechanism in HAE. Different approaches to long-term prophylactic therapy can be used to successfully manage HAE when tailored to meet the needs of the individual patient. Keywords: C1-esterase inhibitor, attenuated androgen, angioedema, HAE, prophylaxis

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results